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Long-term morbidity after hematopoietic cell transplantation (HCT) is unknown. The risk of physical and
psychological health in 324 patients who had survived 10 or more years after HCT and a sibling comparison
group (n ¼ 309) was evaluated. Using the Common Terminology Criteria for Adverse Events, the 15-year
cumulative incidence of severe/life-threatening/fatal conditions was 41% (95% conﬁdence interval, 34% to
48%). HCT survivors were 5.7 times as likely to develop a severe/life-threatening condition (P < .001) and
2.7 times as likely to report somatic distress (P < .001) compared with siblings. Compared with allogeneic
HCT recipients with no chronic graft-versus-host disease (GVHD), those with active chronic GVHD were at
a 1.8-fold higher risk of severe/life-threatening health conditions (P ¼ .006) and a 4.5-fold higher risk of
somatic distress (P ¼ .04); allogeneic HCT recipients with resolved chronic GVHD were not at increased risk of
morbidity compared with those with no chronic GVHD. Only 27% of the HCT survivors returned to the
transplantation center for their cancer-related care. The burden of long-term physical and emotional
morbidity borne by survivors remains substantial, even beyond 10 years after HCT; however, specialized
health care is underused. Patients, families, and healthcare providers need to be made aware of the high
burden, so they can plan for post-HCT care, even many years after HCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION 1998 for a hematological malignancy or severe aplastic anemia (SAA), had
An increasing number of individuals with hematological
malignancies receive hematopoietic cell transplantations
(HCTs) as a curative option. With the improvement in patient
selection, transplantation strategies, and supportive care
options, two thirds of those who survive the ﬁrst 2 years
after HCT become long-term survivors [1-3]. However, high-
intensity therapeutic exposures (among allogeneic HCT
recipients) combined with the consequences of chronic
graft-versus-host disease (GVHD) increase the risk of long-
term morbidity after HCT. We have previously demonstrated
that the cumulative incidence of chronic health conditions
increaseswith increasing time after HCT [4], and survivors are
more likely to report somatic distress [5]when comparedwith
their age-matched siblings. However, physical and psycho-
logical healthandtheconsequenthealthcareneeds inpatients
who have survived extended lengths of time after HCT are
unknown. Using the resources offered by the Bone Marrow
Transplantation Survivor Study (BMTSS), we determined the
prevalence and severity of chronic health conditions,
psychological well-being, and status of healthcare utilization
in patients who have survived 10 or more years after HCT.
METHODS
Subjects
Eligible participants included individuals who had received HCT at City
of Hope (COH) or the University of Minnesota (UMN) between 1974 anddgments on page 1079.
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13.04.002survived at least 10 years post-transplantation, were 18 years or older and
alive at study participation, and were English-speaking. Comparison with
a noncancer population was made possible by recruiting siblings to the
study.
In the HCT survivor questionnaire packet, a “sibling identiﬁcation” form
was included. This form requested the survivor (or the parent of patients
<18 years of age) to identify all siblings (along with their names, gender,
date of birth, and address) who would be willing to participate in this study.
A stratiﬁed random sample of siblings was created, based on the distribution
of HCT survivors (age at study participation, gender, racial/ethnic back-
ground). Within each stratum, siblings were sampled sequentially and the
nearest-age siblings included. A BMTSS sibling questionnaire was mailed
(offered) to the siblings.
The Human Subjects Committee at the participating institutions
approved the protocol. Informed consent was provided according to the
Declaration of Helsinki.
Clinical Characteristics
Information regarding primary diagnosis, preparative regimens, stem
cell source (autologous, sibling, or unrelated donor), graft type (bone
marrow or peripheral blood stem cells), risk of relapse at HCT (standard or
high risk), and prophylaxis for andmanagement of GVHDwas obtained from
institutional databases. Patients received transplantations in ﬁrst or second
complete remission after acute myeloid or lymphoid leukemia, Hodgkin’s
lymphoma or non-Hodgkin lymphoma, ﬁrst chronic phase of chronic
myeloid leukemia, and patients with SAA were considered at standard-risk
for relapse. The remainder were considered at high risk.
Bone Marrow Transplantation Survivor Study Questionnaire
HCT survivors and siblings completed a 255-item questionnaire, which
covered the following general areas: sociodemographic characteristics
(race/ethnicity, education, marital status, employment, household income,
and insurance), diagnosis of speciﬁc physical health conditions, presence or
absence of active chronic GVHD in the preceding 12 months, access to and
use of medical care, self-reported health status (poor, fair, good, or excel-
lent), and self-reported psychological health status (described below). TheTransplantation.
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responses have demonstrated a high level of sensitivity and speciﬁcity,
conﬁrming that survivors are able to report the occurrence of adverse
medical conditions with accuracy [6].
Chronic Health Conditions
The BMTSS questionnaire included questions regarding diagnosis by
a healthcare provider of physical health conditions (endocrinopathies,
central nervous system compromise, cardiopulmonary dysfunction,
gastrointestinal and hepatic sequelae, musculoskeletal complications, and
subsequent malignancies) with age at diagnosis. Chronic physical health
conditions diagnosed after HCT were graded using the Common Termi-
nology Criteria for Adverse Events, version 3.0 [7], which has been used to
grade health conditions in cancer survivors [4,8] and distinguishes grades 1
through 5 with unique clinical descriptions of the severity for each event
(grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening/
disabling; grade 5, death due to chronic health conditions). The same
scoring systemwas applied to responses from the sibling comparison group.
A detailed description of the questions asked in the BMTSS question-
naire, the corresponding chronic health condition categories that were
created from the responses, and the scoring of these conditions are pre-
sented in Supplemental Table S1. Gonadal failure was not included as
a chronic health condition in this analysis, primarily because of the over-
whelmingly high prevalence (>90%) of gonadal failure in HCT survivors,
which would have rendered the rest of the analysis inassessable by masking
the prevalence of other chronic health conditions. Because the goal of this
analysis focused on chronic health conditions, external causes of death
(homicide, suicide, accident) or relapse of primary disease were not
included as grade 5 conditions.
Psychological Outcomes
Psychological health status was evaluated using the Brief Symptom
Inventory-18 (BSI-18) [9]. BSI-18 measures psychological distress by using
18 items on a 5-point Likert scale (from 0 ¼ “not at all” to 4 ¼ “extremely”)
related to symptoms experienced during the previous 7 days (Supplemental
Table S2) [9]. BSI-18 has been validated in healthy volunteers [10] and in
cancer patients [9,11].
Healthcare Utilization
Healthcare utilization in the 2 years preceding the survey was assessed
in 3 domains: (1) general contact with the healthcare system (medical
contact), (2) general physical examination (GPE), and (3) cancer/HCT-related
visit. These outcomes were not mutually exclusive. General or nonspeciﬁc
medical contact was ascertained by asking the respondent if he or she had
contact with a physician, nurse, or other healthcare provider in the 2 years
before the survey. The contact could include a visit to the physician’s ofﬁce
or a phone contact. GPE was deﬁned as a self-report of physical examination
within the 2 years before survey. To ascertain a cancer/HCT-related visit, the
respondents were asked whether they received their health care at an
oncology (cancer) center or clinic and whether they had any physician visits
that were related to their previous cancer or HCT. A response in the afﬁr-
mative to either of these 2 questions qualiﬁed as “yes” to a cancer/HCT-
related visit.
Statistical Analyses
Prevalence of chronic health conditions
The prevalence of chronic health conditions was determined for
participating HCT survivors (n¼ 324) and the sibling comparison group (n¼
309). Chronic health conditions were reported as presence of any chronic
health condition (grades 1 through 4) and dichotomized as mild-to-
moderate (grade 1 or 2) and severe/life-threatening/disabling (grade 3 or
4). For participants with more than 1 condition, the maximum grade was
used in the analysis. Standard parametric and nonparametric techniques
were used for comparisons between clinical and demographic subgroups.
Cumulative incidence of chronic health conditions among HCT survivors
To provide an estimate of the magnitude of risk of chronic health
conditions among HCT recipients with time from HCT, cumulative incidence
of chronic health conditions was calculated. This analysis included the 324
patients who completed the BMTSS survey and the 51 patients who died
after having survived 10 years post-HCT and were therefore not available for
completion of the BMTSS survey. For patients who were alive at study
participation (n ¼ 324), self-reported chronic health conditions were used
for the analyses (as described above). For the deceased patients, all deaths
due to chronic health conditions (n¼ 37) were considered as grade 5; deaths
due to primary disease, accident, or suicide (n ¼ 14) were not graded.
Cumulative incidence calculations considered death from causes other thanchronic health conditions as a competing risk according to the method
described by Gooley et al. [12].
Prevalence of psychological outcomes
BSI-18 includes 3 subscales, depression, anxiety, and somatization (each
with 6 items; scores ranging from 0 to 24), and a summary scale, the Global
Severity Index (18 items, with scores ranging from 0 to 72). Higher scores
indicate higher symptom levels. To facilitate interpretation, raw scores were
converted to gender-speciﬁc T-scores (mean ¼ 50, standard deviation ¼ 10)
based on a community sample of 1134 adults. Patients with T-scores for the
Global Severity Index 63 (90th percentile) were classiﬁed as having
signiﬁcant psychological distress. Similarly, for each subscale, patients with
T-scores 63 were classiﬁed as having distress in the corresponding
subscale [13,14].
Suicidal ideation was elicited as part of the BSI-18 depression subscale.
Participants who endorsed the question “thoughts of ending your life” were
considered to have suicidal ideation. To evaluate the association between
depression and suicidal ideation, an alternative method was used to calcu-
late the depression scale by treating suicidal ideation as a missing item and
then scoring the depression scale using published missing data rules [9].
Predictors of chronic health conditions and psychological outcomes
Comparisons between HCT survivors and siblings after adjusting for
gender, age at study participation (treated as a continuous variable), race/
ethnicity (non-Hispanic whites versus others), education (<high school,
high school/some college/training, or college graduate/postgraduate
education), annual household income (<$20,000 per year, $20,000 to
$60,000 per year, and >$60,000 per year), and health insurance status (yes/
no) were conducted using relative risk regression for common outcomes
and were reported as relative risks (RR) with 95% conﬁdence intervals (CIs)
for chronic health conditions [15]. The analysis accounted for within-family
correlations using sandwich standard error estimates [16]. Logistic regres-
sion techniques were used for psychological outcomes; odds ratios (ORs)
with 95% CIs were reported.
Relative risk regression and logistic regression were also used for
analyses restricted to HCT survivors. A ﬁxed set of explanatory variables
were selected a priori and were used to assess their simultaneous impact on
the risk of chronic health conditions or adverse psychological outcomes.
These variables included gender, age at study participation (40 years, 41 to
55 years,>55 years), age at HCT (<18 years,18 to<45 years,45), time since
HCT (10 to 15 years, 16 to 20 years, >20 years), race (non-Hispanic whites,
others), education, health insurance coverage, primary cancer diagnosis,
transplanting institution (COH, UMN), risk of relapse at HCT (standard or
high), year of HCT (before or after 1990), stem cell donor source (autologous,
related, and unrelated donor), and exposure to total body irradiation (TBI).
Analysis stratiﬁed by stem cell donor source (autologous, allogeneic) was
also conducted. History of chronic GVHD and the presence of active/resolved
chronic GVHD were examined in an analysis restricted to allogeneic HCT
survivors only.
Data were analyzed using SAS 9.2 (SAS Institute, Cary, NC). All statistical
tests were two-sided, and P < .05 was considered statistically signiﬁcant.
RESULTS
A total of 648 patients underwent HCT at COH or UMN
between 1974 and 1998, and survived at least 10 years; 51
patients died after surviving 10 years. Of the 597 survivors
who were alive at study participation, 494 (83%) were
successfully contacted and 324 (66%) participated in the
study. Participants were older at HCT (mean age: 25 versus
22 years, P ¼ .04) than nonparticipants. Patients who had
undergone HCT for SAA were less likely to participate
compared with survivors with other diagnoses (41% versus
57%, P ¼ .03). However, participants and nonparticipants did
not differ by time from HCT to study participation (15.2
versus 15.7 years, P ¼ .9), race (non-Hispanic whites: 81.5%
versus 81.0%, P ¼ .12), gender (women: 44% versus 39%, P ¼
.14), type of HCT (autologous HCT recipients: 28% versus 24%,
P ¼ .9), or transplanting institution (P ¼ .44).
The demographic and clinical characteristics of the entire
cohort are presented in Table 1; characteristics by stem cell
donor type are summarized in Supplemental Table S3. The
median age of the HCT survivors at study participation was
40.9 years (range: 19 to 72), and the median length of follow-
up was 14.5 years (range: 10 to 28). Primary diagnoses
Table 1
Demographic and Clinical Characteristics of HCT Survivors Who Have
Survived 10 Years and Siblings
Characteristic Survivors
(n ¼ 324 )
Siblings
(n ¼ 309)
P
Sex <.001
Male 180 (55.6%) 113 (36.6%)
Race* .02
Non-Hispanic white 264 (81.5%) 270 (88.0%)
Others 60 (18.5%) 37 (12.0%)
Education* .001
Less than high school 21 (6.5%) 5 (1.6%)
High school/some
college or training
172 (53.3%) 130 (42.2%)
College graduate/
postgraduate
130 (40.2%) 173 (56.2%)
Household income* <.001
>$60,000/yr 124 (41.6%) 189 (64.3%)
$20-60,000/yr 130 (43.6%) 93 (31.6%)
<$20,000/yr 44 (14.8%) 12 (4.1%)
Health insurance* .01
Yes 284 (88.8%) 291 (95.1%)
Age at study participation, yr <.001
Mean (SD) 39.7  11.4 44.8  11.8
Median (range) 40.9 (18.5-72.2) 45.2 (19.3-78.8)
Age at HCT, yr
Mean (SD) 24.5  12.3 NA
Median (range) 25.9 (.4-59.8) NA
Interval between HCT and study, yr
Mean (SD) 15.2  3.9 NA
Median (range) 14.5 (10-28) NA
Primary cancer diagnosis
SAA 37 (11.4%) NA
CML 62 (19.1%) NA
AML 88 (27.2%) NA
HL 26 (8.0%) NA
NHL 38 (11.7%) NA
ALL 57 (17.6%) NA
Others 16 (4.9%) NA
Institution
COH 137 (42.3%)
UMN 187 (57.7%)
Stem cell source
Autologous HCT 92 (28.4%) NA
Bone marrow 54 (16.7%)
PBSC 16 (4.9%)
Both 22 (6.8%)
Allogeneic 232 (71.6%)
Allogeneic, related 220 (67.9%) NA
Allogeneic, unrelated 12 (3.7%) NA
Risk of relapse at HCT*
Standard risk 230 (71.4%) NA
High risk 92 (28.6%) NA
Preparative regimens: All myeloablative
Chemotherapy alone 78 (24.2%) NA
TBI-based 244 (75.8%) NA
TBI/cyclophosphamide 140 (43.2%) NA
TBI/cyclophosphamide/
etoposide
36 (11.1%) NA
TBI/etoposide 24 (7.4%) NA
Chronic GVHDy
No 136 (58.6%) NA
Yes active 26 (11.2%) NA
Yes resolved 70 (30.2%) NA
Any immunosuppressiony 224 (96.6%) NA
Methotrexate 177 (76.6%) NA
Cyclosporine 72 (31.2%) NA
Prednisone 143 (61.9%) NA
SAA indicates severe aplastic anemia; CML, chronic myelogenous leukemia;
AML, acute myeloid leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin
lymphoma; ALL, acute lymphoblastic leukemia.
Values are total number of subjects, unless otherwise noted. NA indicates
not applicable. Percentages are based on the total number of participants
who provided data for each variable, rather than on the total number of
subjects in each cohort; percentages may not total 100 because of rounding.
* Two siblings with unknown race, two with unknown education (1
survivor and 1 sibling), 41 (26 survivors and 15 siblings) with unknown
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leukemia (19%), acute lymphoid leukemia (18%), non-Hodgkin
lymphoma (12%), SAA (11%), Hodgkin’s lymphoma (8%), and
other diagnoses (5%). Twenty-eight percent of the patients
received autologous HCT; 68% were allogeneic related and 4%
received unrelated donor HCT. Bone marrow with or without
peripheral blood stem cells was the stem cell source for 76 of
94 autologous HCT recipients (81%); bone marrow was the
stem cell source for all allogeneic HCT recipients. All patients
received myeloablative conditioning; 76% of the patients
received TBI-based conditioning. Compared with siblings,
HCT survivors were more likely to be men, to be younger at
study participation, to have lower education, to have lower
annual household income, and were less likely to have health
insurance.
Chronic Health Conditions
Table 2 summarizes the prevalence of chronic health
conditions among 10þ year survivors and siblings. At least 1
chronic health condition was reported by 74% of the HCT
survivors, compared with 39% of siblings (P < .001). Further-
more, 25% of survivors reported severe/life-threatening
conditions compared with only 8% of siblings (P < .001).
Commonly reported severe/life-threatening chronic health
conditions included myocardial infarction, stroke, blindness,
diabetes, musculoskeletal problems, and subsequent malig-
nancies. Comparedwith siblings, HCTsurvivorswere 2.2 times
as likely (95% CI ¼ 1.8 to 2.5, P < .001) to report a grade 1 to 4
condition but 5.7 times as likely to report a severe/life-
threatening condition (95% CI ¼ 3.8 to 8.7, P < .001) after
adjustment for age at participation, gender, race/ethnicity,
education, annual household income, and insurance status.
The prevalence of speciﬁc types of severe/life-threatening
chronic health conditions for the entire cohort and by stem
cell source is summarized in Supplemental Table S4. There
was no signiﬁcant difference in the prevalence of the broad
categories of severe/life-threatening conditions between
autologous and allogeneic HCT recipients. Although not
statistically signiﬁcantly different, autologous HCT recipients
were more likely to report coronary artery disease, signiﬁ-
cant hearing loss, and second malignancies. On the other
hand, allogeneic HCT recipients were more likely to report
a stroke, signiﬁcant visual impairment, hepatic cirrhosis,
diabetes, and osteonecrosis that necessitated joint
replacements.
In the analysis restricted to HCT survivors (Table 3),
non-Hispanic whites were more likely to report mild-to-
moderate chronic health conditions. Furthermore, HCT
survivors with health insurance (RR¼ 2.6, 95% CI¼ 1.2 to 5.9,
P ¼ .02) and those exposed to TBI for conditioning (RR ¼ 3.0,
95% CI ¼ .9 to 9.6, P ¼ .07) were more likely to report severe/
life-threatening conditions. No risk factors were identiﬁed in
the analysis restricted to autologous HCT recipients
(Supplemental Table S5). Among allogeneic HCT recipients
(Supplemental Table S6), survivors with health insurance
(RR ¼ 2.6, 95% CI ¼ 1.0 to 6.8, P ¼ .05), those exposed to TBI
for conditioning (RR ¼ 1.7, 95% CI ¼ 1.0 to 3.1, P ¼ .06), and
those with chronic GVHD (RR ¼ 1.4, 95% CI ¼ 1.0 to 1.9, P ¼
.04) were more likely to report severe/life-threateningincome, 7 with unknown insurance (4 survivors and 3 siblings), 2 survivors
with unknown risk of relapse, and 2 survivors with unknown preparative
regimens were excluded.
y Among allogeneic HCT recipients only.
Table 2
Chronic Health Conditions, Psychological Outcomes, and Healthcare Utilization among HCT Survivors Who Have Survived 10 Years and Siblings
HCT Survivors Siblings (n ¼ 309) P:
All Survivors
versus Siblings
Autologous
(n ¼ 92)
Allogeneic
(n ¼ 232)
P:
Autologous versus Allogeneic
All Survivors
(n ¼ 324)
Health condition*,y
No condition 29 (31.5%) 55 (23.7%) .58 84 (25.9%) 189 (61.2%) <.001
Grade 1 8 (8.7%) 28 (12.1%) 36 (11.1%) 45 (14.6%)
Grade 2 34 (37.0%) 87 (37.5%) 121 (37.4%) 51 (16.5%)
Grade 3 16 (17.4%) 47 (20.3%) 63 (19.4%) 15 (4.9%)
Grade 4 5 (5.4%) 15 (6.5%) 20 (6.2%) 9 (2.9%)
Psychological distress
Somatization 7 (7.6%) 28 (12.1%) .24 35 (10.8%) 12 (3.9%) .001
Anxiety 0 11 (4.7%) .04 (exact) 11 (3.4%) 8 (2.6%) .55
Depression 6 (6.5%) 19 (8.2%) .61 25 (7.7%) 14 (4.5%) .10
Global distress 3 (3.3%) 16 (6.9%) .30 (exact) 19 (5.9%) 10 (3.2%) .11
Healthcare utilization
Medical contact 91 (98.9%) 231 (99.6%) .49 322 (99.4%) 308 (99.7%) 1.00
GPE 72 (78.3%) 177 (76.3%) .70 249 (76.9%) 243 (78.6%) .59
Cancer/HCT visit 54 (58.7%) 128 (55.2%) .56 182 (56.2%) 6 (1.9%) <.001
Health status
Excellent/good 82 (89.1%) 201 (87.0%) .60 283 (87.6%) 292 (94.5%) .003
Fair/poor 10 (10.9%) 30 (13.0%) 40 (12.4%) 17 (5.5%)
* The severity of health conditions was scored according to the Common Terminology Criteria for Adverse Events (version 3). Health conditions of HCT
survivors did not include conditions that patients had before HCT or acute conditions they had within 2 years after the HCT.
y The number of patients in each subgroup may not reﬂect the sum of grades of conditions, because grades 1 to 4 were calculated by taking the maximum
grade per subject. A subject with higher grade condition may have other lower grade conditions.
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survivors without chronic GVHD, those with active chronic
GVHD were 1.8 times more likely to report severe/life-
threatening conditions (RR ¼ 1.8, 95% CI ¼ 1.2 to 2.7, P ¼
.006), whereas those with resolved chronic GVHD were not
more likely to report severe/life-threatening conditions
(RR ¼ 1.3, 95% CI ¼ .9 to 1.8, P ¼ .22).
As shown in Figure 1, the 15-year cumulative incidence
of any chronic health condition (grades 1 to 5) was 71% (95%
CI ¼ 66% to 76%) and of severe/life-threatening conditions
or death due to these conditions was 41% (95% CI ¼ 34% to
48%). The cumulative incidence of any chronic health
condition or severe/life-threatening condition did not differ
by stem cell donor type (P ¼ .79, P ¼ .65, Figure 2A, B,
respectively). However, among allogeneic HCT recipients,
the cumulative incidence of any chronic health conditions
and severe/life-threatening conditions was signiﬁcantly
higher among those with chronic GVHD as compared with
those without chronic GVHD (P ¼ .01, P < .001, Figure 3A, B,
respectively). The chronic health conditions reported by
HCT recipients with a history of chronic GVHD included
diabetes, coronary artery disease, stroke, ocular complica-
tions resulting in signiﬁcant visual impairment, and osteo-
necrosis necessitating joint replacement. Among autologous
HCT recipients, the cumulative incidence of any chronic
health condition (grades 1 to 5) (P ¼ .5) and of severe/life-
threatening conditions or death due to these conditions
(P ¼ .6) did not differ by exposure to TBI-based conditioning
regimens.
Psychological Distress
Using BSI-18, we evaluated somatic distress, anxiety, and
depression among HCT survivors and the sibling comparison
group (Table 2). Although the prevalence of anxiety (3.4%
versus 2.6%) and depression (7.7% versus 4.5%) were
comparable between survivors and siblings, HCT survivors
were 2.7 times more likely to report somatic distress (10.8%
versus 3.9%, P < .001). In the analysis restricted to HCTsurvivors, female gender (OR ¼ 3.6, 95% CI ¼ 1.4 to 9.0, P ¼
.01), low annual household income (<$20,000 OR ¼ 4.4, 95%
CI ¼ 1.1 to 17.2, P ¼ .03), and poor self-rated health status
(OR ¼ 10.6, 95% CI ¼ 4.0 to 27.9, P < .001) were associated
with increased risk for somatic distress. Among survivors
who underwent allogeneic HCT, those with active chronic
GVHD were more likely to report somatic distress (OR ¼ 4.5,
95% CI ¼ 1.1 to 18.5, P ¼ .04), whereas those with resolved
chronic GVHD were not at risk for reporting somatic distress
(OR ¼ 1.9, 95% CI ¼ .6 to 6.0, P ¼ .3).
In this cohort of long-term survivors, 23 HCT recipients
(7%) expressed suicidal ideation as compared with 7 siblings
(2%) (P ¼ .004). Adjustment for gender, health status,
household income, and chronic health conditions eliminated
the difference between survivors and siblings (P ¼ .23). Of
these 23 HCT recipients reporting suicidal ideation, 73% were
men and 83% reported at least 1 chronic health condition.
HCT survivors with depression were 13-fold more likely to
report suicidal ideation compared with survivors without
depression (95% CI ¼ 4.9 to 36.0, P < .001) after adjustment
for gender and current health status.
Healthcare Utilization
Table 2 summarizes the pattern of healthcare utilization
and perceived health status among 10þ year survivors and
siblings. Despite their reported high prevalence of chronic
health conditions and somatic distress, 88% of the 10þ year
survivors perceived their health status as excellent/good. The
comparable ﬁgure in siblings was 95% (P¼ .003). Eighty-nine
percent of the HCT survivors and 95% of the siblings carried
health insurance coverage. Almost all survivors (99.4%) and
siblings (99.7%) reported medical contact in the 2 years
before study participation. Furthermore, a comparable
number of survivors (77%) and siblings (79%) reported GPE in
the 2 years before study participation. However, even at an
average of 15 years after HCT, 56% of the HCT survivors (n ¼
182) reported cancer/HCT-related visits. The corresponding
ﬁgures in autologous and allogeneic HCT survivors were
Table 3
Relative Risk of Chronic Health Conditions among HCT Survivors
Risk Factors Grades 1-4 Grades 1-2 Grades 3-4
RR (95% CI) RR (95% CI) RR (95% CI)
Stem cell donor
Autologous 1.0 1.0 1.0
Allogeneic, related 1.00 (.8-1.2) .92 (.7-1.2) 1.05 (.6-1.8)
Allogeneic, unrelated .98 (.7-1.4) .92 (.6-1.2) 1.19 (.6-2.6)
Gender
Male 1.0 1.0 1.0
Female 1.11 (.98-1.3) 1.15 (.96-1.4) 1.29 (.95-1.8)
Age at study participation, yr
40 1.0 1.0 1.0
41-55 1.02 (.9-1.2) 1.00 (.8-1.3) .95 (.6-1.5)
>55 .89 (.7-1.2) .85 (.5-1.4) .81 (.4-1.5)
Age at HCT, yr
<18 1.0 1.0 1.0
18-<45 1.03 (.8-1.3) 1.03 (.8-1.4) 1.25 (.7-2.2)
45 1.43 (.8-2.4) 1.70 (.8-3.6) 1.44 (.4-5.3)
Time since HCT, yr
10-15 1.0 1.0 1.0
16-20 1.05 (.9-1.2) 1.06 (.8-1.4) 1.10 (.7-1.7)
20 1.19 (.96-1.5) 1.36 (.99-1.9) 1.30 (.8-2.1)
Race
Others 1.0 1.0 1.0
Non-Hispanic white 1.30 (1.0-1.7) 1.52 (1.0-2.2) 1.27 (.8-2.1)
Education
<High school 1.0 1.0 1.0
High school to some
college
1.28 (.8-1.97) 1.35 (.8-2.4) 1.42 (.6-3.6)
College graduates 1.27 (.8-1.97) 1.37 (.8-2.4) 1.37 (.5-3.5)
Insurance
No 1.0 1.0 1.0
Yes 1.28 (.96-1.7) 1.23 (.9-1.8) 2.61 (1.2-5.9)
Institution
COH 1.0 1.0 1.0
UMN 1.16 (.98-1.4) 1.15 (.9-1.5) 1.51 (1.0-2.2)
Relapse risk at HCT
Low risk 1.0 1.0 1.0
High risk .96 (.8-1.1) .90 (.7-1.1) 1.12 (.8-1.6)
Year of transplantation
Before 1990 1.0 1.0 1.0
After 1990 .95 (.8-1.2) .98 (.8-1.3) .75 (.5-1.2)
TBI-containing regimens
Chemotherapy only 1.0 1.0 1.0
TBI-based regimen 1.17 (.9-1.5) 1.17 (.9-1.6) 2.98 (.9-9.6)
Primary cancer diagnosis
SAA 1.0 1.0 1.0
CML 1.03 (.7-1.5) 1.17 (.7-1.9) .41 (.1-1.6)
AML .99 (.7-1.4) 1.02 (.7-1.5) .55 (.2-2.0)
HL .93 (.6-1.4) .87 (.5-1.5) .78 (.3-2.2)
NHL .80 (.5-1.2) .62 (.3-1.1) .44 (.1-2.1)
ALL .89 (.6-1.3) .85 (.5-1.4) .38 (.1.-1.5)
Others 1.14 (.8-1.7) 1.26 (.8-2.1) .55 (.2-2.0)
SAA indicates severe aplastic anemia; CML, chronic myelogenous leukemia;
AML, acute myeloid leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin
lymphoma; ALL, acute lymphoblastic leukemia.
Adjusted for all variables in the table.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
10 11 12 13 14 15 16 17 18 19 20
Years after HCT
C
u
m
u
la
t
iv
e
 I
n
c
id
e
n
c
e
 (
%
)
71% (15 yr)
Any chronic 
health condition
41% (15 yr)
Severe/life-threatening 
condition or death
Figure 1. Cumulative incidence of chronic health conditions among 10þ year
survivors.
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of the HCT survivors (n ¼ 88) reported that their
cancer/HCT-related visits were at the transplantation center.
No signiﬁcant difference was found in terms of using
a transplantation center for their cancer/HCT-related visits
by transplantation type (33% among autologous HCT survi-
vors versus 25% among allogeneic HCT survivors, P ¼ .2). The
prevalence of severe/life-threatening conditions was
comparable between those who reported cancer/HCT-
related visits (26%) and those who did not (25%) (P ¼ .96).
DISCUSSION
HCT is used as a viable therapeutic option for several
hematological malignancies [17]. Steadily improving survivalrates [1-3] and the attendant growth in long-term survivors
have turned the attention to the health and well-being of the
survivors many years after HCT and, consequently, the
patterns of healthcare utilization by these survivors.
Although the health and psychological well-being of these
survivors has been explored previously, there is a paucity of
this information among HCT recipients who have survived
for extended periods of time. The current study demon-
strates that the burden of long-term physical and emotional
morbidity borne by 10þ year HCT survivors is substantial. At
15 years post-HCT, the cumulative incidence for developing
any chronic health condition approached 71%; for severe/
life-threatening/fatal conditions, the cumulative incidence
approached 41%. These 10þ year survivors were at a 5.7-fold
increased risk of reporting severe/life-threatening conditions
and at a 2.7-fold increased risk of reporting somatic distress
compared with siblings. Finally, although 59% of survivors
received cancer-related care within 2 years before study
participation, only 27% returned to the transplantation
center for this care.
An important observation in this study was the high
prevalence of chronic health conditions among autologous
HCT recipients; 23% of the autologous HCT recipients de-
veloped severe/life threatening conditions, compared with
27% of the allogeneic HCT recipients. Allogeneic HCT recipi-
ents were more likely to have received TBI, and those
without chronic GVHD were younger at study participation,
compared with autologous HCT recipients. Finally, allogeneic
HCT recipients had been followed for a longer time, primarily
because allogeneic HCTs have been performed since themid-
1970s at the 2 participating institutions, whereas the ﬁrst
autologous HCTs were performed in the early 1980s. All these
factors could have possibly contributed to a comparable
burden of morbidity between the 2 groups. Although autol-
ogous HCT recipients were more likely to report coronary
artery disease (likely due to pre-HCT chest radiation [18]),
hearing loss (platinum-based therapy for lymphoma
patients), and newmalignancies (therapy-related leukemia),
allogeneic HCT recipients were more likely to report osteo-
necrosis (prolonged exposure to steroids and calcineurin
inhibitors), visual impairment (exposure to steroids and TBI),
hepatic cirrhosis (hepatitis C virus activation in the setting of
immune suppression), stroke, and diabetes (higher preva-
lence of cardiovascular risk factors among allogeneic HCT
recipients). Thus, these data indicate that most chronic
health conditions after autologous HCT likely arose as a result
of pre-HCT therapeutic exposures, whereas those observed
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Figure 2. Cumulative incidence of chronic health conditions among 10þ year survivors. (A) Grades 1-5 by stem cell donor source. (B) Grades 3-5 by stem cell donor
source.
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related events, such as conditioning with TBI and develop-
ment of chronic GVHD after HCTand the immunosuppressive
therapy needed to manage it. However, because of logistical
issues, we were unable to procure detailed information
regarding pre-HCT therapy exposures.
The cumulative incidence of any chronic health condition
and of severe/life-threatening conditions was signiﬁcantly
higher among those with chronic GVHD as compared with
those without it. Furthermore, compared with allogeneic
HCT survivors without chronic GVHD, those with active
chronic GVHD were 1.8 times more likely to report severe/
life-threatening conditions, whereas those with resolved
chronic GVHD were not at increased risk. Thus, the highest
burden of morbidity was borne by allogeneic HCT recipients
with active chronic GVHD; the 15-year cumulative incidence
of any chronic health condition approached 78%; for severe/
life-threatening/fatal conditions, the cumulative incidence
approached 54%. In addition, allogeneic HCT recipients with
active chronic GVHDwere at a 4.5-fold higher risk of somatic
distress, when compared with those without chronic GVHD.
Chronic health conditions reported by HCT recipients with
chronic GVHD included diabetes, coronary artery disease,
stroke, ocular complications that resulted in signiﬁcant
visual impairment, and osteonecrosis that necessitated joint
replacement. The signiﬁcant inﬂuence of active chronic
GVHD on both the physical and psychological health burden0%
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Figure 3. Cumulative incidence of chronic health conditions among 10þ year alloge
chronic GVHD status.borne by 10þ year survivors and mitigation of morbidity
(both physical and psychological) among thosewith resolved
chronic GVHD further emphasize the critical need for
a multidisciplinary approach to manage GVHD.
HCT survivors exposed to TBI were 3 times more likely to
report severe/life-threatening conditions. TBI-exposed sur-
vivors reported diabetes, hepatic cirrhosis, osteonecrosis,
and renal failure. Several studies have demonstrated an
increased risk of diabetes among those exposed to TBI
[18-24] and among those exposed to abdominal radiation
[25,26]. There are several mechanisms by which abdominal
irradiation (directed or as part of TBI) may lead to diabetes
mellitus. Radiation could cause pancreatic insufﬁciency as
evidenced by degranulation, vacuolization, mitochondrial
destruction, and impaired insulin secretion by the islet cells
after exposure to radiation in animal studies [27,28]. The
relationship between osteonecrosis and TBI has been re-
ported [29,30]. Osteonecrosis is likely due to vascular
damage secondary to TBI. Radiation is known to induce both
a reduction in the number of osteoblasts and microvascular
changes due to subintimal ﬁbrosis and thickening of the
median layer of small vessels [31]. Renal dysfunction has
been recognized as a complication of HCT for the past 2
decades, and the association between chronic kidney disease
and radiation nephritis as a consequence of exposure toTBI is
well-established [32,33], with a direct doseeresponse rela-
tionship [34]. Cirrhosis of the liver has been described after0%
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neic HCT survivors. (A) Grades 1-5 by chronic GVHD status. (B) Grades 3-5 by
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[35,36]. However, previous studies have not explored expo-
sure to TBI as a risk factor for potentiating hepatitis C
viruserelated cirrhosis of the liver.
Eighty-nine percent of the 10þ year survivors carried
health insurance. Similar to the ﬁndings in a previous study
[4], the current study found that those with health insurance
were more likely to report conditions, such as stroke,
congestive heart failure, severe hearing loss, liver cirrhosis,
diabetes, and osteonecrosis. This observation can be inter-
preted within the context of relying on self-report of chronic
health conditions; thus, the study depends on the availability
of adequate health care to identify chronic health conditions
and therefore the ability of the HCT survivors to report them.
HCT survivors were at a 2.7-fold higher risk of reporting
somatic distress compared with siblings, after accounting for
the presence of chronic health conditions. Women, those
with low household income, those with poor self-reported
health status, and, among allogeneic HCT recipients, those
with active chronic GVHD were at high risk of reporting
somatic distress. Finally, 7% of HCT survivors expressed
suicidal ideation, compared with 2% of siblings; 83% of HCT
survivors with suicidal ideation reported chronic health
conditions. Furthermore, HCT survivors with self-reported
depression were 13 times more likely to report suicidal
ideation compared with those without depression. Given the
high morbidity after HCT and difﬁculty in resuming gainful
employment, survivors with low income are especially
vulnerable to poor psychological outcomes. Adequate sup-
port should be provided to these survivors to alleviate
psychological problems. HCT survivors were less likely to
perceive their health status as good/excellent (88%) when
compared with siblings (95%). The fact that self-reported
impaired health status was associated with somatic
distress, independent of chronic health conditions, calls for
close attention to the reasons for survivors’ self-rated health
status.
Although over 99% of HCT survivors maintained some
level of medical contact, only 27% (33% of the autologous HCT
recipients and 25% of the allogeneic HCT recipients) returned
to the transplantation center for management of ongoing
health issues in the 2 years before study participation. This
could be because of distance from the center, ofﬁcial transi-
tion of care by the transplanting team to the primary care
physician, or the expiration of the contractual arrangement
between the patients’ insurance carrier and transplantation
center. The observation that a large proportion of autologous
and allogeneic HCT recipients do not return to the trans-
plantation center for long-term care (despite the high
burden of morbidity) emphasizes the need for ensuring that
standardized recommendations [37] for the follow-up of this
vulnerable population are disseminated to the primary care
physicians assuming responsibility for the care of these
patients. Furthermore, there is a need for the transplantation
team to develop an ongoing partnership with the primary
care physicians, as patients are transitioned from the trans-
plantation center, to ensure that comprehensive care is
delivered long term to survivors.
There have been signiﬁcant changes in transplantation
conditioning regimens and drugs used for GVHD prophylaxis
as well as management over the past 2 to 3 decades. Thus,
the use of TBI for conditioning has declined for both autol-
ogous and allogeneic HCT recipients. The number of patients
receiving unrelated HCTs has increased, with an associated
increase in the prevalence of those with chronic GVHD.Finally, the drugs used for management of GVHD have also
changed. However, it is important to capture and report the
burden of morbidity carried by our long-term survivors
so we can develop adequate resources to manage them.
Furthermore, even though transplantation strategies have
changed, older agents (such as TBI and GVHD medications)
continue to be used, although fewer patients are receiving
them. It is therefore critical that transplanting physicians
(and the new HCT recipients) be aware of the long-term risks
of these agents, so appropriate intervention strategies can be
instituted as needed.
In conclusion, the burden of long-term physical and
psychological morbidity borne by 10þ year HCT survivors is
substantial, creating a need to ensure that life-long special-
ized health care is available for survivors. Patients, families,
and healthcare providers need to be made aware of the high
burden to plan for post-HCT care, even many years after HCT.
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